Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

About this update from Mesoblast Limited

[{"type":"image","alt":"Mesoblast Limited","displaySize":"","headline":null,"caption":"Mesoblast Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":289,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qVvwFFYM1KHQf5WBcCEDQw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3a26a2f63129fae6650ef7618b48c2df","width":289,"height":38}},"lazy":false},{"type":"text","content":"Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year Facility","length":77,"tagName":"p"},{"type":"text","content":"NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil® (remestemcel-L-rknd) sales for the quarter ended December 31, 2025.1 This represents a 60% increase on the prior quarter ended September 30, 2025.","length":367,"tagName":"p"},{"type":"text","content":"Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication. Ryoncil® is the only FDA-approved product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD),2 and will now be evaluated in a pivotal trial as part of a second-line regimen for adults with SR-aGvHD, a market approximately three times larger than the pediatric market.","length":455,"tagName":"p"},{"type":"text","content":"The increase in quarterly revenues continues to strengthen Mesoblast's balance sheet after the Company announced it entered into a US$125 million facility with its largest shareholder which substantially lowered the company’s cost of capital and freed up its major assets to provide flexibility for strategic partnerships and commercialization.","length":348,"tagName":"p"},{"type":"text","content":"The new facility enabled Mesoblast to repay in full its prior senior secured loan. Additionally, Mesoblast partly repaid its subordinated royalty facility which will continue to reduce from ongoing revenue and will be fully repaid by mid-CY2026. The new US$125 million five-year interest-only facility has a substantially lower overall cost compared with previous facilities, ...

More updates from Mesoblast Limited